Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 12/20 | 0.53 |
| ▸ | SLC2A3 | P11169 | 12/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173601 | 1.00 | SLC2A1 (0.53) | SLC2A1SLC2A3ROCK2ROCK1SYK | |
| SCHEMBL27249066 | 0.88 | ROCK2 (0.52) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL27248767 | 0.87 | SLC2A1 (0.51) | SLC2A1SLC2A3SYKDGAT1NPC1 | |
| SCHEMBL27248907 | 0.86 | HDAC3 (0.51) | SLC2A1SLC2A3ROCK2ROCK1SYK | |
| SCHEMBL27248739 | 0.86 | SLC2A1 (0.49) | SLC2A1SLC2A3ROCK2ROCK1SYK | |
| SCHEMBL27249103 | 0.85 | ROCK2 (0.57) | SLC2A1SLC2A3ROCK2ROCK1DGAT1 | |
| SCHEMBL27248648 | 0.81 | JAK1 (0.49) | SLC2A1SLC2A3SYKDGAT1NPC1 | |
| SCHEMBL27248662 | 0.80 | SLC2A1 (0.52) | SLC2A1SLC2A3ROCK2ROCK1SYK | |
| SCHEMBL27248806 | 0.79 | SLC2A1 (0.59) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL27249080 | 0.78 | SLC2A3 (0.67) | SLC2A1SLC2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | SLC2A1 1/4885SLC2A3 4/4885ROCK2 3701/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | SLC2A1 1/4885SLC2A3 4/4885ROCK2 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.